Park Avenue Securities LLC Grows Position in Boston Scientific Corporation $BSX

Key Points

• Park Avenue Securities LLC increased its stake in Boston Scientific by 7.6%, holding 49,581 shares worth approximately $5.3 million after acquiring an additional 3,499 shares in Q2.
• Boston Scientific reported earnings of $0.75 EPS, exceeding analyst expectations of $0.72, with revenues of $5.06 billion in the last quarter, reflecting a 22.8% increase from the previous year.
• Insider transactions included significant stock sales by executives, with Edward J. Ludwig selling 4,000 shares and Joseph Michael Fitzgerald selling 50,000 shares, indicating a decrease in their respective holdings.

Park Avenue Securities LLC boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 7.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 49,581 shares of the medical equipment provider's stock after purchasing an additional 3,499 shares during the period. Park Avenue Securities LLC's holdings in Boston Scientific were worth $5,325,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. 1248 Management LLC purchased a new stake in Boston Scientific during the 1st quarter worth approximately $26,000. Y.D. More Investments Ltd purchased a new stake in Boston Scientific during the 1st quarter worth approximately $27,000. Ameriflex Group Inc. acquired a new stake in Boston Scientific during the 4th quarter valued at approximately $31,000. Oliver Lagore Vanvalin Investment Group acquired a new stake in Boston Scientific during the 2nd quarter valued at approximately $37,000. Finally, Activest Wealth Management lifted its stake in Boston Scientific by 6,216.7% during the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider's stock valued at $38,000 after acquiring an additional 373 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $96.91 on Tuesday. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The firm has a market capitalization of $143.60 billion, a price-to-earnings ratio of 57.69, a PEG ratio of 2.36 and a beta of 0.65. The company has a fifty day simple moving average of $104.25 and a 200-day simple moving average of $102.08. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the firm earned $0.62 earnings per share. The company's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director owned 18,479 shares of the company's stock, valued at $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,802,597.06. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $18,397,457 over the last three months. 0.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on BSX. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. UBS Group lifted their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Needham & Company LLC restated a "buy" rating and set a $121.00 price objective on shares of Boston Scientific in a research note on Friday. Finally, Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $118.04.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.